We are excited to introduce our new preclinical model of chemotherapy-induced peripheral neuropathy (CIPN) using Paclitaxel, developed to support your research in neuropathic pain and drug development.
👉Why Paclitaxel-induced neuropathy matters?
Paclitaxel (Taxol®) is a widely used chemotherapy drug for treating breast, ovarian, and lung cancers. It works by stabilizing microtubules, disrupting cell division, and causing cell cycle arrest, which leads to the death of rapidly dividing cancer cells.
However, paclitaxel also causes significant side effects, with peripheral neuropathy being one of the most debilitating. By disrupting microtubule function in neurons, paclitaxel damages peripheral nerves, particularly sensory neurons, leading to symptoms such as hyperalgesia (increased pain sensitivity) and allodynia (pain from non-painful stimuli).
This chronic neuronal toxicity severely impacts patients’ quality of life and can sometimes lead to discontinuation of chemotherapy.
The new paclitaxel-induced peripheral neuropathy model helps researchers understand these mechanisms and test the effectiveness of novel analgesics to alleviate these severe side effects.
👉Key Features of the Paclitaxel-Induced Neuropathy Model
✅Reproducibility & High Translatability:
- The model reliably mimics the clinical manifestations of neuropathy observed in human patients, including mechanical hyperalgesia and thermal allodynia.
✅Robust Experimental Design:
- Rats receive repeated intraperitoneal administrations of paclitaxel (2 mg/kg on D0, D2, D4, and D7) to induce consistent neuropathic behaviors.
- Testing involves well-validated endpoints like paw pressure thresholds.
✅Drug Testing Paradigm:
- The model supports both acute and chronic drug administration protocols.
- Reference compounds like Duloxetine and Morphine demonstrate clear efficacy, validating the model’s sensitivity.
✅Rapid Data Turnaround:
- Preliminary results available within one week after completion of the experimental phase.
- Comprehensive study reports are delivered within three weeks, ensuring timely insights.
👉Pharmacological results
👉Special Offer: 10% Discount!
To help you get started with this new model, we are offering a 10% discount on any study signed before June 30, 2025.
Don’t miss out on this exclusive opportunity to save while advancing your research.
Thank you for choosing ANS Biotech as your trusted partner in preclinical pain pharmacology!
👉 Interested in learning more?
Contact us today!
Stay ahead in pain research with ANS Biotech!